RTI-371: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:RTI-371.svg|RTI-371 | |||
</gallery> | |||
Latest revision as of 01:49, 20 February 2025
RTI-371 is a stimulant drug that is used in scientific research. It is a selective dopamine transporter inhibitor, but unlike other DAT inhibitors such as cocaine and methylphenidate, RTI-371 is not a psychostimulant, and instead has anti-addictive effects. This makes it a useful research tool for studying the role of the dopamine transporter in the brain.
Pharmacology[edit]
RTI-371 is a potent and selective inhibitor of the dopamine transporter, which is responsible for the reuptake of dopamine in the brain. By inhibiting this transporter, RTI-371 increases the amount of dopamine available in the brain. Unlike other DAT inhibitors, however, RTI-371 does not produce psychostimulant effects, and instead has been found to have anti-addictive properties in animal studies.
Uses[edit]
RTI-371 is primarily used in scientific research to study the role of the dopamine transporter in the brain. It has been used in studies investigating the effects of DAT inhibitors on drug addiction, and has been found to reduce self-administration of cocaine in rats.
Side Effects[edit]
As a research chemical, the side effects of RTI-371 are not well-studied. However, as a DAT inhibitor, it may potentially cause side effects similar to other drugs in this class, such as increased heart rate and blood pressure.
See Also[edit]
References[edit]
<references />


